Trending Assets
Top investors this month
Trending Assets
Top investors this month
$12.6MFollowers
Inspire Medical ($INSP) Q1 Earnings Recap
Financials
Revenue increased by 84% YoY, an acceleration sequentially and the best quarterly increased in two years. In turn, management raised full year guidance by 3.5% at the midpoint, to $585MM.
I said in my Q3 earnings recap (posted on Nov 1, 2022) that my guess was they'd finally achieve positive full year FCF in 2023 and GAAP net profitability in 2024. Well, they beat me to the punch by squeaking out $2.5MM in FCF in 2022. Net profitability in 2023 will be tough but they increased their EBT margin by 1,200bps. FCF improved by even more. For a company already putting out gross margins above 83%, they have so much operating leverage room left.
US revenue continues to be the lion's share, coming in at >97% of total revenue. Call me crazy but people in countries outside of the US suffer from sleep apnea so I see it only as a matter of time before international revenue begins to accelerate rapidly.
Highlights from the call/quarter
- In March they announced FDA approval for pediatric patients with down syndrome. This expands their treatment for people with Down syndrome from aged 18 and up to aged 13 and up.
- Also in March they announced countrywide reimbursement in Belgium. This is just one step in what I see to be an avalanche of international approvals over the next 10+ years.
- They completed their first two cases in Hong Kong in Q1 and have been "pleased with progress in Singapore." Turning to Japan, they moved to a direct sales organization and are seeing "good momentum with strong patient outcomes and growing patient flow."
- They committed to submitting the FDA application for the Inspire V by the end of Q2 and are planning for early 2024 approval.
investors.inspiresleep.com
Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in Belgium
MINNEAPOLIS, March 09, 2023 (GLOBE NEWSWIRE) - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today that it has received countrywide reimbursement approval in Belgium, effective immediately, at rates consistent with other countries around the world. “The healthcare team at Antwerp University Hospital (UZA
I'm curious what the other Commonstock $INSP shareholders (@michaelbaker165) or former shareholders (@naveed @plombard6 @scidem) or people with Inspire Medical on their watchlists think of Q1.
Already have an account?